Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Short term Debt (2016 - 2023)

Arcadia Biosciences' Short term Debt history spans 10 years, with the latest figure at $15000.0 for Q1 2023.

  • For Q1 2023, Short term Debt fell 78.26% year-over-year to $15000.0; the TTM value through Mar 2023 reached $15000.0, down 78.26%, while the annual FY2022 figure was $48000.0, 25.0% down from the prior year.
  • Short term Debt reached $15000.0 in Q1 2023 per RKDA's latest filing, down from $48000.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $1.1 million in Q1 2021 to a low of $12000.0 in Q1 2019.
  • Average Short term Debt over 5 years is $229941.2, with a median of $40000.0 recorded in 2019.
  • The largest YoY upside for Short term Debt was 7031.25% in 2021 against a maximum downside of 94.18% in 2021.
  • A 5-year view of Short term Debt shows it stood at $40000.0 in 2019, then skyrocketed by 2650.0% to $1.1 million in 2020, then crashed by 94.18% to $64000.0 in 2021, then fell by 25.0% to $48000.0 in 2022, then tumbled by 68.75% to $15000.0 in 2023.
  • Per Business Quant, the three most recent readings for RKDA's Short term Debt are $15000.0 (Q1 2023), $48000.0 (Q4 2022), and $47000.0 (Q3 2022).